Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases | Zendy

Silje Watterdal Syversen | Zendy; Guro Løvik Goll | Zendy; Kristin Kaasen Jørgensen | Zendy; Øystein Sandanger | Zendy; Joseph Sexton | Zendy; Inge Christoffer Olsen | Zendy; Johanna Elin Gehin | Zendy; David J. Warren | Zendy; Marthe Kirkesæther Brun | Zendy; Rolf Anton Klaasen | Zendy; Lars Normann Karlsen | Zendy; Geir Noraberg | Zendy; Camilla Zettel | Zendy; M. K. A. Ljosa | Zendy; Anne Julsrud Haugen | Zendy; Rune Johan Njålla | Zendy; Trude Jannecke Bruun | Zendy; Kathrine Aglen Seeberg | Zendy; Brigitte Michelsen | Zendy; Eldri Kveine Strand | Zendy; Svanaug Skorpe | Zendy; Ingrid Marianne Blomgren | Zendy; Yngvill Hovde Bragnes | Zendy; Christian Kvikne Dotterud | Zendy; Turid Thune | Zendy; Carl Magnus Ystrøm | Zendy; Roald Torp | Zendy; Paweł Mielnik | Zendy; Cato Mørk | Zendy; Tore K Kvien | Zendy; Jørgen Jahnsen | Zendy; Nils Bolstad | Zendy; Espen A. Haavardsholm | Zendy

Open Access

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

Author(s) -

Silje Watterdal Syversen,

Guro Løvik Goll,

Kristin Kaasen Jørgensen,

Øystein Sandanger,

Joseph Sexton,

Inge Christoffer Olsen,

Johanna Elin Gehin,

David J. Warren,

Marthe Kirkesæther Brun,

Rolf Anton Klaasen,

Lars Normann Karlsen,

Geir Noraberg,

Camilla Zettel,

M. K. A. Ljosa,

Anne Julsrud Haugen,

Rune Johan Njålla,

Trude Jannecke Bruun,

Kathrine Aglen Seeberg,

Brigitte Michelsen,

Eldri Kveine Strand,

Svanaug Skorpe,

Ingrid Marianne Blomgren,

Yngvill Hovde Bragnes,

Christian Kvikne Dotterud,

Turid Thune,

Carl Magnus Ystrøm,

Roald Torp,

Paweł Mielnik,

Cato Mørk,

Tore K Kvien,

Jørgen Jahnsen,

Nils Bolstad,

Espen A. Haavardsholm

Publication year - 2021

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2021.4172

Subject(s) - medicine , infliximab , ulcerative colitis , therapeutic drug monitoring , randomized controlled trial , psoriatic arthritis , rheumatoid arthritis , pharmacotherapy , psoriasis , dosing , maintenance therapy , adalimumab , inflammatory bowel disease , disease , pharmacokinetics , chemotherapy , immunology

Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab and other biological drugs. However, whether proactive TDM improves clinical outcomes when implemented at the time of drug initiation, compared with standard therapy, remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research